The Women in Bio (WIB) Greater Boston 11th Annual Lobster P... Laura Allred
Read More What We Learned at the 11th Annual Women in Bio Lobster Pot Pitch: Emerging Trends in Biotech Innovation and Investment
“Lighthouse Hubs” Can Create Specialized Clusters in Europe ...
When experts from across Europe sit around one table to deba... Frauke Graalfs
Read More “Lighthouse Hubs” Can Create Specialized Clusters in Europe to Elevate Particular Sub-Disciplines in the ATMP-Field
Which Financial Solution Is Right for You? A Guide for Biotech L...
Whether you’re a startup navigating early fundin...
Read More Which Financial Solution Is Right for You? A Guide for Biotech Leaders
Smart Leasing Strategies for Growth-Phase Companies
The scientific landscape is undergoing a lot of change and c...
Read More Smart Leasing Strategies for Growth-Phase Companies
Balancing Progress and Cash Flow: How One Pharmaceutical Company...
Pharmaceutical companies often face long timelines and ...
Read More Balancing Progress and Cash Flow: How One Pharmaceutical Company Optimized Funding with an Extended Terms Agreement
Mastering Long-Term Innovation with Master Lease Agreements
Innovation in both academia and industry depends on timely a...
Read More Mastering Long-Term Innovation with Master Lease Agreements
How Biotech Startups Can Stretch Funding and Still Scale
For emerging biotech startups, progress depends on capital e...
Read More How Biotech Startups Can Stretch Funding and Still Scale
When Funding Gets Cut, Research Shouldn’t Stop—And Neither W...
In the unpredictable world of biotech, one constant remains:...
Read More When Funding Gets Cut, Research Shouldn’t Stop—And Neither Will We
How to Use Monoclonal Antibodies with Autoimmune Diseases
Monoclonal antibodies (mAbs) are transforming how autoimmune... Archana Gupta, Ph.D.
Read More How to Use Monoclonal Antibodies with Autoimmune Diseases
Molecule to Market: What Biotech Leaders Need Most at Each Phase...
Most biotech companies share a similar ambition throughout d... Jenny Ro
Read More Molecule to Market: What Biotech Leaders Need Most at Each Phase of Drug Development